Printer Friendly

SPI PRESIDENT TELLS SPANISH TRADE DELEGATION COMPANY GROWTH LINKED TO EUROPEAN EXPANSION

 SPI PRESIDENT TELLS SPANISH TRADE DELEGATION
 COMPANY GROWTH LINKED TO EUROPEAN EXPANSION
 IRVINE, Calif., May 19 /PRNewswire/ -- Adam Jerney, president and chief operating officer of SPI Pharmaceuticals Inc. (AMEX: SPI) today told a high-ranking delegation of trade officials from Spain that SPI's new, $17 million state-of-the-art pharmaceutical manufacturing facility near Barcelona heralds the expansion of the California pharmaceutical firm in Europe.
 Jerney spoke at a luncheon sponsored by the World Trade Center Association of Orange County and ENISA, the Industrial Development Corp. for Spain. Dignitaries at the event included Eugenio Triana, Secretary General of Industry for Spain, and top ministers of Spain's commerce, economy and other governmental units.
 In March 1992, SPI officially opened its Barcelona plant, as a further step in the company's growing European operations. The facility is built and equipped to meet GMP (Good Manufacturing Practice) standards, allowing SPI to significantly increase its role in the Spanish pharmaceutical market, as well as throughout other Western and Eastern European markets, Jerney said.
 SPI's Spanish subsidiary, which operates in Spain as ICN Hubber, was established as the result of the 1987 acquisition of Hubber Laboratories.
 The Spanish facility makes antiviral pharmaceuticals, anti-ulcer and cholesterol-lowering medications, among other products. It employs 280, Jerney said. SPI also has manufacturing facilities in The Netherlands and Yugoslavia.
 Jerney said SPI's investment in Spain is a "major step in expanding our European presence." He said Spain currently has one of the top 10 economies in the world. "It is the most forward-looking country in Europe today," he said.
 The visiting Spanish dignitaries also were given a tour of SPI headquarters in Costa Mesa.
 SPI Pharmaceuticals Inc., headquartered in Costa Mesa, Calif., manufactures, markets and distributes 600 prescription and non- prescription pharmaceuticals in over 60 countries, including North and Latin America, Western and Eastern Europe and the Far East.
 -0- 5/19/92
 /CONTACT: Jack Sholl of SPI Pharmaceuticals, 714-545-0100, ext. 3013/
 (SPI) CO: SPI Pharmaceuticals Inc. ST: California IN: MTC SU:


AL -- LA017 -- 1923 05/19/92 14:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:336
Previous Article:REACTION TO HR.5100: BILL'S AUTO QUOTA WOULD SACRIFICE AMERICAN JOBS, CONSUMERS' POCKETBOOKS TO PROTECT BIG THREE MARKETSHARE
Next Article:HOLIDAY SAFETY: PENNSYLVANIA TURNPIKE PRIORITY; MOTORISTS NEAR BREEZEWOOD CAN EXPECT MAJOR DELAYS
Topics:


Related Articles
SPI PHARMACEUTICALS SIGNS LETTER OF INTENT WITH RUSSIAN PHARMACEUTICAL COMPANY AS PART OF ITS PLANNED EXPANSION IN THE U.S.S.R.
RUSSIA AUTHORIZES VIRAZOLE FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS
SPI PHARMACEUTICALS EXPECTS 1991 SALES TO REACH $360 MILLION
/C L A R I F I C A T I O N -- SPI PHARMACEUTICALS/
ICN PHARMACEUTICALS OPENS NEW SPANISH PLANT AS PART OF EUROPEAN EXPANSION
SPI'S MEXICAN SUBSIDIARY ANNOUNCES $5 MILLION EXPANSION
SPI PHARMACEUTICALS INTRODUCES TREATMENT FOR OSTEOPOROSIS IN MEXICO
SPI PHARMACEUTICALS WINS BID FOR STAKE IN LEADING HUNGARIAN DRUG MANUFACTURER
SPI PHARMACEUTICALS INTRODUCES THIRD GENERATION ANTIBIOTIC IN MEXICO
Rhone-Poulenc Rorer Sells Two Manufacturing Facilities to SPI Polyols

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters